To the Editor:Intrahepatic cholangiocarcinoma(ICC)ranks second among liver malignancies,and system chemotherapy is the current choice for controlling the tumor for patients with advanced ICC.[1]Gemcitabine(Gem)-based ...To the Editor:Intrahepatic cholangiocarcinoma(ICC)ranks second among liver malignancies,and system chemotherapy is the current choice for controlling the tumor for patients with advanced ICC.[1]Gemcitabine(Gem)-based chemotherapy has been a dominating treatment for advanced ICC.[2]Generally,the outcome of systemic chemotherapy is poor and dissatisfied,and patients easily obtain therapy resistance.[2]Recently,programmed cell death 1(PD-1)blockade has shown great potential in tumor-specific immune therapy.[3]Lenvatinib which targets multi-vascular endothelial growth factor receptors(VEGFR),and lenvatinib alliance of PD-1 blockade have shown great promise in advanced ICC.[4]This retrospective multicenter research compares the prognosis of triple therapy with Gemox,lenvatinib,and PD-1 blockade with Gemox monotherapy for treating ICC with extrahepatic metastases.展开更多
基金supported by a grant from National Natural Science Foundation of China(No.82102082).
文摘To the Editor:Intrahepatic cholangiocarcinoma(ICC)ranks second among liver malignancies,and system chemotherapy is the current choice for controlling the tumor for patients with advanced ICC.[1]Gemcitabine(Gem)-based chemotherapy has been a dominating treatment for advanced ICC.[2]Generally,the outcome of systemic chemotherapy is poor and dissatisfied,and patients easily obtain therapy resistance.[2]Recently,programmed cell death 1(PD-1)blockade has shown great potential in tumor-specific immune therapy.[3]Lenvatinib which targets multi-vascular endothelial growth factor receptors(VEGFR),and lenvatinib alliance of PD-1 blockade have shown great promise in advanced ICC.[4]This retrospective multicenter research compares the prognosis of triple therapy with Gemox,lenvatinib,and PD-1 blockade with Gemox monotherapy for treating ICC with extrahepatic metastases.
